T-Cell Receptor Discovery Technology Platform
Our innovative T-Cell Receptor (TCR) technology platform is enabling the fast and efficient discovery and qualification of a large number of high-affinity and high-specificity TCRs that can be used for Adoptive Cell Therapies i.e. ACTengine® and ACTallo® and Bispecific TCR Molecule development.
In addition, Immatics has established powerful capabilities in TCR engineering, generating TCRs with affinities within the low nM range, while retaining the molecules natural specificity. The resulting ultra-high-affinity TCRs are utilized for soluble formats such as Immatics Bispecific TCRs.